Search: (WFRF:(Ohm Lotta)) >
Dasatinib induces f...
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
-
- Hjorth-Hansen, Henrik (author)
- St Olavs Hospital, Norway; Norwegian University of Science and Technology NTNU, Norway
-
- Stenke, Leif (author)
- Karolinska Institutet
-
- Söderlund, Stina (author)
- Uppsala universitet,Hematologi,University of Uppsala Hospital, Sweden
-
show more...
-
- Dreimane, Arta (author)
- Linköpings universitet,Institutionen för medicin och hälsa,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US
-
- Ehrencrona, Hans (author)
- Lund University,Lunds universitet,Avdelningen för klinisk genetik,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Clinical Genetics,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital, Sweden
-
- Gedde-Dahl, Tobias (author)
- University of Oslo, Norway
-
- Gjertsen, Bjorn Tore (author)
- Haukeland Hospital, Norway; University of Bergen, Norway
-
- Höglund, Martin (author)
- Uppsala universitet,Hematologi,University of Uppsala Hospital, Sweden
-
- Koskenvesa, Perttu (author)
- University of Helsinki, Finland; University of Helsinki, Finland
-
- Lotfi, Kourosh (author)
- Linköpings universitet,Avdelningen för läkemedelsforskning,Hälsouniversitetet,Region Östergötland, Klinisk farmakologi
-
- Majeed, Waleed (author)
- Stavanger University Hospital, Norway
-
- Markevarn, Berit (author)
- Umeå University Hospital, Sweden
-
- Ohm, Lotta (author)
- Karolinska University Hospital, Sweden; Karolinska Institute, Sweden
-
- Olsson-Strömberg, Ulla (author)
- Uppsala universitet,Hematologi,University of Uppsala Hospital, Sweden
-
- Remes, Kari (author)
- Turku University, Finland
-
- Suominen, Merja (author)
- Kanta Hame Central Hospital, Finland
-
- Simonsson, Bengt (author)
- Uppsala universitet,Hematologi,University of Uppsala Hospital, Sweden
-
- Porkka, Kimmo (author)
- University of Helsinki, Finland; University of Helsinki, Finland
-
- Mustjoki, Satu (author)
- University of Helsinki, Finland; University of Helsinki, Finland
-
- Richter, Johan (author)
- Lund University,Lunds universitet,Avdelningen för molekylärmedicin och genterapi,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Molecular Medicine and Gene Therapy,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital, Sweden
-
show less...
-
(creator_code:org_t)
- 2014-09-13
- 2015
- English.
-
In: European Journal of Haematology. - : Wiley. - 1600-0609 .- 0902-4441. ; 94:3, s. 243-250
- Related links:
-
https://portal.resea... (primary) (free)
-
show more...
-
http://dx.doi.org/10... (free)
-
https://onlinelibrar...
-
https://doi.org/10.1...
-
https://uu.diva-port... (primary) (Raw object)
-
https://liu.diva-por... (primary) (Raw object)
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
https://urn.kb.se/re...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive dasatinib 100mg QD or imatinib 400mg QD and report outcome as an intention-to-treat analysis with 36months follow-up. Early cytogenetic and molecular responses were superior in the dasatinib group, with a tendency that imatinib patients caught up with time. For instance, MR3.0 was reached at 3months in 36% vs. 8% (P=0.02), at 12months in 81% vs. 46% (P=0.02) and at 18months in 73% vs. 65% (n.s.) of the patients in the two groups. In contrast, MR4.5 was consistently superior in the dasatinib group at all time points from 6months onwards, reaching 61% vs. 21% (P<0.05) at 36months. Sixty-four vs. 71% of the patients in the dasatinib and imatinib arms, respectively, remained on assigned drug. Dasatinib dose was frequently reduced, but with maintained excellent effect. One imatinib patient progressed to blastic phase, but no CML-related deaths occurred. In conclusion, our data compare favourably with those of the dasatinib registration study, DASISION. The fast and deep molecular responses induced by dasatinib compared with imatinib may be exploited to increase the proportion of patients who can achieve a treatment-free remission after treatment discontinuation.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Keyword
- dasatinib
- imatinib
- randomized controlled trial
- deep response
- toxicity
- dasatinib; imatinib; randomized controlled trial; deep response; toxicity
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database
- By the author/editor
-
Hjorth-Hansen, H ...
-
Stenke, Leif
-
Söderlund, Stina
-
Dreimane, Arta
-
Ehrencrona, Hans
-
Gedde-Dahl, Tobi ...
-
show more...
-
Gjertsen, Bjorn ...
-
Höglund, Martin
-
Koskenvesa, Pert ...
-
Lotfi, Kourosh
-
Majeed, Waleed
-
Markevarn, Berit
-
Ohm, Lotta
-
Olsson-Strömberg ...
-
Remes, Kari
-
Suominen, Merja
-
Simonsson, Bengt
-
Porkka, Kimmo
-
Mustjoki, Satu
-
Richter, Johan
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Hematology
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
- Articles in the publication
-
European Journal ...
- By the university
-
Lund University
-
Uppsala University
-
Linköping University
-
Karolinska Institutet